[COPD inhaled therapy narrative review]. / Revisión narrativa de la terapia inhalatoria en la EPOC.
Semergen
; 50(7): 102284, 2024 Jun 25.
Article
em Es
| MEDLINE
| ID: mdl-38925076
ABSTRACT
The basis of COPD maintenance treatment is the long-acting bronchodilators and the inhaled corticosteroids. Faced with the recent modifications in the clinical practice guidelines, we have carried out a review of studies that contrast the various therapeutic alternatives and pharmacological agents within each category, with the fundamental purpose of shedding light on which of these options prove to be more effective. Triple therapy stands out as essential in poorly controlled patients or with an eosinophilic phenotype, surpassing dual therapy. However, among the combinations of LAMA/LABA or LAMA/LABA/IC, no drug is observed to be superior in the reviewed evidence. Although triple therapies include corticosteroids, there does not appear to be a significant increase in side effects or pneumonia. Regarding monotherapy with LAMA, no significant differences are seen between the drugs, but in dual therapy with LABA/IC, the budesonide/formoterol combination seems to offer better control than fluticasone/salmeterol.
Agonistas ß2 adrenérgicos de acción larga; Anticolinérgicos de acción larga; Chronic obstructive pulmonary disease; Corticoides inhalados; Enfermedad pulmonar obstructiva crónica; Exacerbación; Exacerbation; Inhaled corticosteroids; Inhaler therapy; Long-acting muscarinic antagonist; Long-acting ß agonists; Terapia inhaladora
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
Es
Revista:
Semergen
Ano de publicação:
2024
Tipo de documento:
Article